Los Angeles Capital Management
TARS icon

Los Angeles Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Los Angeles Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
26,291
+410
+2% +$26.2K 0.01% 630
2026
Q1 		$1.82M Sell
25,881
-5,612
-18% -$392K 0.01% 526
2025
Q4 		$2.17M Sell
31,493
-5,609
-15% -$419K 0.01% 430
2025
Q3 		$2.2M Buy
37,102
+13,569
+58% +$668K 0.01% 479
2025
Q2 		$953K Buy
+23,533
New +$1.06M ﹤0.01% 652

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Los Angeles Capital Management's TARS Position: Q2 2026 in Review

Los Angeles Capital Management increased its Tarsus Pharmaceuticals (TARS) stake by 1.6% in Q2 2026, buying an estimated $26.2K and bringing the position to 26,291 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #630.

Los Angeles Capital Management first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.2M in Q3 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Los Angeles Capital Management held 26,291 shares of Tarsus Pharmaceuticals worth $1.65M as of Q2 2026.
  • Los Angeles Capital Management bought 410 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $26.2K.
  • Tarsus Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #630 holding.
  • Los Angeles Capital Management first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Tarsus Pharmaceuticals position peaked at $2.2M in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.